{"transactions":[{"id":726669,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-25T20:04:20.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":4.08,"value":114240.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."}],"balance_after":28000,"derivative":{"exercise_price":4.08,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001972849-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000197284926000004/primarydocument.xml","form_type":"4"}},{"id":1161352,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-05-02T20:04:44.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":4.16,"value":208000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors."}],"balance_after":50000,"derivative":{"exercise_price":4.16,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-25-003475","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000156218025003475/primarydocument.xml","form_type":"4"}},{"id":1271962,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2025-02-12T22:13:24.000Z","date":"2025-02-10","kind":"sale","planned":false,"acquired":false,"shares":4618,"price":15.504,"value":71597.472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":85095,"source":{"system":"sec-edgar","filing":"0000950170-25-018993","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000095017025018993/ownership.xml","form_type":"4"}},{"id":1278923,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2025-02-07T21:45:49.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":110500,"price":14.65,"value":1618825.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":110500,"derivative":{"exercise_price":14.65,"expiration_date":"2035-02-05","underlying":"Common Stock","underlying_shares":110500},"source":{"system":"sec-edgar","filing":"0000950170-25-016391","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000095017025016391/ownership.xml","form_type":"4"}},{"id":1278922,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2025-02-07T21:45:49.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":23400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company."}],"balance_after":89713,"source":{"system":"sec-edgar","filing":"0000950170-25-016391","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000095017025016391/ownership.xml","form_type":"4"}},{"id":1278921,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2025-02-07T21:45:49.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units (\"RSUs\"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested."}],"balance_after":66313,"source":{"system":"sec-edgar","filing":"0000950170-25-016391","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000095017025016391/ownership.xml","form_type":"4"}},{"id":1334217,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-12T22:49:50.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest on date of next annual general meeting following grant date of December 10, 2024."}],"balance_after":31000,"derivative":{"exercise_price":13.06,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000950170-24-135919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000095017024135919/ownership.xml","form_type":"4"}},{"id":1554055,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T01:54:58.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":74000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest in 36 equal monthly installments starting one month after grant date of April 2, 2024."}],"balance_after":74000,"derivative":{"exercise_price":9.23,"expiration_date":"2034-04-01","underlying":"Common Stock","underlying_shares":74000},"source":{"system":"sec-edgar","filing":"0000950170-24-040632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000095017024040632/ownership.xml","form_type":"4"}},{"id":1651894,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2024-02-09T21:05:00.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":69375,"price":22.28,"value":1545675.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":69375,"derivative":{"exercise_price":22.28,"expiration_date":"2034-02-07","underlying":"Common Stock","underlying_shares":69375},"source":{"system":"sec-edgar","filing":"0001562180-24-001221","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000156218024001221/primarydocument.xml","form_type":"4"}},{"id":1651893,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2024-02-09T21:05:00.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":13125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company."}],"balance_after":47813,"source":{"system":"sec-edgar","filing":"0001562180-24-001221","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000156218024001221/primarydocument.xml","form_type":"4"}},{"id":1651892,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Common Stock","published_at":"2024-02-09T21:05:00.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":34688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units (\"RSUs\"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested."}],"balance_after":34688,"source":{"system":"sec-edgar","filing":"0001562180-24-001221","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000156218024001221/primarydocument.xml","form_type":"4"}},{"id":1921179,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":35427,"kind":"person","name":"Gallagher Neil","position":1,"cik":"0001972849","reported_name":"Gallagher Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Head of R&D"}}],"security":"Stock Options (Right to buy)","published_at":"2023-04-12T20:02:44.000Z","date":"2023-04-10","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":19.35,"value":4837500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty five percent (25%) of the total number of shares underlying the option shall vest on April 10, 2024, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates."}],"balance_after":250000,"derivative":{"exercise_price":19.35,"expiration_date":"2033-04-10","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001562180-23-003520","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1972849/000156218023003520/primarydocument.xml","form_type":"4"}}]}